Key result
DOAC continuation did not reduce stroke or systemic embolism compared to discontinuation, but increased major bleeding in patients with no AF recurrence for ≥1 year post-ablation.
Why the study?
Guideline-recommended indefinite DOAC therapy after successful AF ablation is challenged by bleeding risks versus potentially reduced stroke risk post-ablation.
Does DOAC continuation reduce thromboembolic events or increase bleeding compared to DOAC discontinuation in patients with durable freedom from AF recurrence after catheter ablation?
Meta-Analysis (n=2,124)
Does DOAC continuation reduce thromboembolic events or increase bleeding compared to DOAC discontinuation in patients with durable freedom from AF recurrence after catheter ablation?
Answers are grounded in this paper and cite their sources.
In patients with durable freedom from AF recurrence post-ablation, discontinuing DOACs significantly reduces bleeding risk without a significant increase in thromboembolic events.
Background and Aims: Current guidelines advocate for indefinite direct oral anticoagulant (DOAC) therapy after successful catheter ablation for atrial fibrillation (AF), based on the CHA2DS2-VASc score. This strategy is challenged by the inherent bleeding risk of DOAC versus the potentially reduced stroke risk post-ablation. We aimed to compare long-term antithrombotic strategies in patients with durable freedom from AF recurrence. Methods: We conducted a meta-analysis of the ALONE-AF and OCEAN trials enrolling 2124 patients with no documented AF recurrence for ≥1 year after ablation. The trials compared DOAC continuation versus DOAC discontinuation. We calculated pooled risk ratios (RR) with 95% confidence intervals (CI) for primary efficacy (thromboembolic events/all-cause mortality) and safety (bleeding events) outcomes. Results: The meta-analysis found no statistically significant difference between DOAC continuation and DOAC discontinuation for all stroke or systemic embolism (RR 1.36; 95% CI: 0.16-11.38), transient ischemic attack (RR 0.20; 95% CI: 0.03-1.15), myocardial infarction (RR 0.08; 95% CI: 0.00-1.37), and all-cause mortality (RR 1.43; 95% CI: 0.55-3.74). In contrast, DOAC continuation was associated with a significantly higher risk of major bleeding (RR 3.07; 95% CI: 1.05-8.96) and clinically relevant non-major bleeding (RR 2.47; 95% CI: 1.01-6.00). Subgroup analysis confirmed consistent treatment effects. Conclusion: In patients who achieve durable freedom from AF recurrence for at least one year following catheter ablation, the absolute risk of thromboembolic events was very low. Strategies involving the discontinuation of DOACs were associated with a statistically lower risk of bleeding without significant risk of stroke.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) conducted a meta-analysis in Atrial fibrillation post-successful catheter ablation (n=2,124). DOAC continuation vs. DOAC discontinuation (or aspirin) was evaluated on All stroke or systemic embolism (RR 1.36, 95% CI 0.16-11.38). DOAC continuation did not reduce stroke or systemic embolism compared to discontinuation, but increased major bleeding in patients with no AF recurrence for ≥1 year post-ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: